<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The familial condition catecholaminergic polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>) is characterized by episodic bidirectional <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (BVT), polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (PVT), and <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> following adrenergic challenge </plain></SENT>
<SENT sid="1" pm="."><plain>It is associated with mutations involving the cardiac <z:chebi fb="0" ids="8925">ryanodine</z:chebi> receptor (RyR2) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We explored for a slowing of myocardial conduction that could potentially result in a substrate for the spontaneous arrhythmogenesis that was observed following introduction of <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> and <z:chebi fb="111" ids="27732">caffeine</z:chebi> in intrinsically beating murine RyR2-P2328S hearts </plain></SENT>
<SENT sid="3" pm="."><plain>Such pharmacological challenge increased the number of arrhythmic episodes in electrocardiographic recordings from intact anesthetized mice, with the greatest effects in the homozygote RyR2(S/S) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011675'>Arrhythmias</z:hpo> took the form of bigeminy, BVT, monomorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>, and PVT, as found in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Ventricular epicardial conduction velocities (CVs) measured using multielectrode array recordings and maximum action potential upstroke rates, (dV/dt)(max), measured using intracellular microelectrodes were indistinguishable in untreated <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) and RyR2(S/S) </plain></SENT>
<SENT sid="6" pm="."><plain>Pharmacological challenge of RyR2(S/S), but not WT hearts, then reduced CV and (dV/dt)(max) and also revealed a strongly arrhythmic phenotype </plain></SENT>
<SENT sid="7" pm="."><plain>There was no evidence of gross structural or fibrotic changes in either RyR2(+/S) or RyR2(S/S) hearts on light microscopy </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: We associate altered ventricular myocardial CV potentially resulting in arrhythmogenic substrate with arrhythmic properties associated with genetic RyR2 alterations for the first time </plain></SENT>
</text></document>